Financial Performance Summary

Cipla Limited announced its unaudited consolidated financial results for the quarter ended September 30th, 2026 (Q2FY27).

Key Financial Metrics:

| Metric | Q2FY27 | Q2FY26 | Change |

| Income from Operations | INR 7,404 Cr | INR 7,589 Cr | -2% YoY |

| EBITDA | INR 1,388 Cr | INR 1,895 Cr | -26.7% YoY |

| EBITDA Margin | 18.7% | 25.0% | -630 bps YoY |

| PAT | INR 878 Cr | INR 1,351 Cr | -35.0% YoY |

The company reported sequential growth with revenue increasing 4% QoQ and EBITDA margin expanding by 200 basis points QoQ to 18.7%.

Segment-wise Performance

One-India Business (INR 3,516 Cr, +12% YoY):

  • Branded Prescription: Grew at 15% market growth with strong double-digit performance in Respiratory, Urology, Cardiac, Anti-diabetes and Dermatology therapies
  • Trade Generics: Delivered strong double-digit QoQ growth with 15+ new launches this quarter
  • Consumer Health: Anchor brands (Nicotex, Omnigel, Cipladine) maintained leadership positions

North America ($172 Mn, +$10 Mn QoQ):

  • Albuterol ranked No. 1 in overall U.S. Albuterol MDI market with 22% market share
  • FDA approved gAdvair Diskus, the first dry powder inhaler from Cipla's U.S. manufacturing network
  • Entered exclusive partnership with Qilu Pharmaceutical for commercialization of Keytruda biosimilar

One Africa (INR 1,171 Cr, -1% YoY):

  • South Africa Private Market: Secondary growth of 6.5% vs market growth of 5.0%
  • Prescription business maintained No. 2 position

Emerging Markets and Europe ($101 Mn, 0% YoY):

  • Operated in challenging environment with geopolitical uncertainties
  • Demonstrated resilience through strong execution and cost discipline

Financial Position and Investments

Balance Sheet Highlights (Sep-26 vs Sep-25):

  • Equity: INR 35,522 Cr (vs INR 33,025 Cr)
  • Total Debt: INR 699 Cr (includes lease liabilities and borrowings)
  • Cash and Cash Equivalents: INR 10,552 Cr (includes current investments, fixed deposits, margin deposits)
  • Net Cash Position: INR 9,823 Cr
  • Inventory: INR 6,778 Cr (vs INR 6,160 Cr)
  • Trade Receivables: INR 6,000 Cr (vs INR 6,902 Cr)
  • Trade Payables: INR 3,266 Cr (vs INR 3,035 Cr)
  • Net Tangible Assets: INR 8,266 Cr (vs INR 6,996 Cr)
  • Goodwill and Intangibles: INR 7,107 Cr (vs INR 5,374 Cr)

R&D Investments: INR 423 Cr (5.7% of sales), directed toward product filings and key development programs

Management Commentary

Achin Gupta, MD and Global CEO, Cipla Ltd stated: "We are pleased to share that we continue to make considerable progress across our focused markets. In Q2FY27, we delivered global revenues of INR 7,404 Cr with a sequential growth of 4% QoQ, while EBITDA margin expanded by 200 basis points QoQ to 18.7%. Our One-India business grew at solid 12% YoY. Branded Prescription business delivered a robust growth, with key therapies outpacing the market. The U.S. business posted revenue of $172 Mn during the quarter, continuing its sequential growth trajectory. We expect North America performance to remain supported by our upcoming product pipeline. South Africa private market business continued to outperform the market, growing approximately 1.3x faster than the market. We continue to focus on sustained growth in our core businesses, improving productivity, strengthening our pipeline in order to serve patients with trusted, high-quality medicines."

Additional Information

The company will host an earnings conference call on October 27, 2026, at 1600 hrs IST. The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was signed by Rajendra Chopra, Company Secretary.

#Tags: #Cipla #FinancialResults #Pharmaceuticals #Earnings #Healthcare